(Q58286129)

2

0 references

Lieven Annemans

3

0 references

Mark van der Linden

4

0 references

Laurence Nicolas-Spony

5

0 references

Xavier Bresse

Expert Review of Pharmacoeconomics & Outcomes Research

6

0 references

publication date

October 2012

0 references

published in

0 references

volume

12

0 references

issue

5

0 references

page(s)

645-660

0 references

cites work

Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention

1 reference

Why it is still important that countries know the burden of pneumococcal disease

21 January 2018

1 reference

Pneumococcal vaccination for older adults: the first 20 years

21 January 2018

1 reference

Pneumococcal disease in western Europe: burden of disease, antibiotic resistance and management

21 January 2018

1 reference

Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults

21 January 2018

1 reference

The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly.

21 January 2018

1 reference

Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.

21 January 2018

1 reference

Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination.

21 January 2018

1 reference

Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults

21 January 2018

1 reference

Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease.

21 January 2018

1 reference

The Immunogenicity of 7‐Valent Pneumococcal Conjugate Vaccine versus 23‐Valent Polysaccharide Vaccine in Adults Aged 50–80 Years

21 January 2018

1 reference

Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory

21 January 2018

1 reference

Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia

21 January 2018

1 reference

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.

21 January 2018

1 reference

[Epidemiology of acute bacterial meningitis in adult patients in France].

21 January 2018

1 reference

Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study

21 January 2018

1 reference

Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults

21 January 2018

1 reference

Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis.

21 January 2018

1 reference

Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds

21 January 2018

1 reference

Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan

21 January 2018

1 reference

Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions

21 January 2018

1 reference

Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey

21 January 2018

1 reference

Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race

21 January 2018

1 reference

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

21 January 2018

1 reference

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

21 January 2018

1 reference

Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete

21 January 2018

1 reference

Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe

21 January 2018

1 reference

Serotype-specific problems associated with pneumococcal conjugate vaccination

21 January 2018

1 reference

Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003.

21 January 2018

1 reference

Seasonal Patterns of Invasive Pneumococcal Disease

21 January 2018

1 reference

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

21 January 2018

1 reference

The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults

21 January 2018

1 reference

Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.

21 January 2018

1 reference

Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits

21 January 2018

1 reference

Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study

21 January 2018

1 reference

New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality

21 January 2018

1 reference

Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network

21 January 2018

1 reference

Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis

21 January 2018

1 reference

The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis

21 January 2018

1 reference

[Long-term follow-up of bacterial meningitis - sequels in children and adults: incidence, type, and assessment issues].

21 January 2018

1 reference

Economic Evaluation of Standing Order Programs for Pneumococcal Vaccination of Hospitalized Elderly Patients

21 January 2018

1 reference

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

21 January 2018

1 reference

Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage

21 January 2018

1 reference

Cost-benefit analysis of pediatric cochlear implantation: German experience.

21 January 2018

1 reference

Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada.

21 January 2018

1 reference

Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective

21 January 2018

1 reference

Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany

21 January 2018

1 reference

The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.

21 January 2018

1 reference

Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial

21 January 2018

1 reference

Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people

21 January 2018

1 reference

Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996–2006

21 January 2018

1 reference

Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years

21 January 2018

1 reference

Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged ≥65 years in the Netherlands

21 January 2018

1 reference

Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–74 years living in Alaska: No evidence of hyporesponsiveness☆☆☆

21 January 2018

1 reference

Molecular characterization of macrolide- and multidrug-resistant Streptococcus pyogenes isolated from adult patients in Barcelona, Spain (1993-2008)

21 January 2018

1 reference